Ptc Therapeutics Stock Price, News & Analysis

PTC Therapeutics, Inc. (NASDAQ: PTCT) revealed findings on the impact of caring for children with aromatic L-Amino acid decarboxylase deficiency (AADC-d) at the Virtual ISPOR North America 2021 Conference. The study highlights that caregivers dedicate an average of 105 hours weekly to support, often leading 75% to leave jobs or reduce hours. The findings underscore the critical need for effective treatments, as AADC-d causes severe disabilities and requires constant care. Data also show a positive correlation between treatment efficacy and improved health outcomes for affected children.

PTC Therapeutics (PTCT) reported a strong Q1 2021 with total revenues of $117.9 million, a 32% increase from Q1 2020. The Duchenne muscular dystrophy (DMD) franchise revenue reached $90 million, driven by new patient uptake and geographic expansion. Preliminary results from the PTC518 trial showed a positive dose-dependent reduction in Huntington mRNA. However, the net loss for Q1 2021 was $128.6 million, compared to $112.7 million a year earlier. PTC reaffirms its 2021 guidance, projecting DMD net product revenues between $355 and $375 million.

PTC Therapeutics (NASDAQ: PTCT) has announced its participation in several upcoming virtual investor conferences. The presentations include:

• BofA Securities 2021 Virtual Health Care Conference on May 11 at 8:45 a.m. ET
• 2021 RBC Capital Markets Global Healthcare Virtual Conference on May 18 at 10:20 a.m. ET
• 2021 UBS Global Healthcare Virtual Conference on May 26 at 12:00 p.m. ET

These presentations will be available live and archived on PTC's investor relations website for 30 days.

PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call on May 4, 2021, at 4:30 p.m. (ET) to discuss its first quarter 2021 financial results. Investors can access the call by dialing (877) 303-9216 domestically or (973) 935-8152 internationally. The call will be available for replay on the company’s website for 30 days after the event. PTC emphasizes its focus on developing differentiated medicines for rare disorders, reinforcing its commitment to providing best-in-class treatments for patients with unmet medical needs.

PTC Therapeutics (NASDAQ: PTCT) has granted stock options for 75,085 shares and 33,740 restricted stock units (RSUs) to 79 new employees as a part of their compensation package. Approved on April 13, 2021, these inducement grants comply with NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $47.31, based on the stock's closing price on the grant date. The vesting period spans four years, with a portion vesting annually and quarterly, contingent on continued employment.

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced positive results from Part 2 of the pivotal FIREFISH trial for Evrysdi™ (risdiplam) in infants with type 1 spinal muscular atrophy (SMA). After 24 months, 93% of infants were alive, with 83% surviving without permanent ventilation. Key motor milestones improved significantly, such as sitting without support (from 29% at 1 year to 61% at 2 years). The treatment was associated with fewer hospitalizations, and safety profiles remained consistent. Evrysdi promotes SMN protein production, crucial for healthy motor neuron function.

PTC Therapeutics (NASDAQ: PTCT) has launched the PTC Pinpoint Direct™-CP Spectrum, a no-charge genetic testing program for individuals in the U.S. with symptoms of cerebral palsy (CP) but without evidence of brain injury. This initiative aims to reduce misdiagnosis and connect patients with potential genetic disorders, which may have existing treatments. The program collaborates with Genome Medical for genetic counseling and Invitae for genetic testing, enhancing patient access to care and eliminating unnecessary treatments.

PTC Therapeutics, Inc. (NASDAQ: PTCT) has been awarded the 2021 Don Clifton Strengths-Based Culture Award by Gallup. This recognition honors organizations that excel in developing engaging workplace cultures focused on employee strengths. CEO Stuart Peltz emphasized the company's commitment to a collaborative environment, especially amid challenges posed by the COVID-19 pandemic. PTC is dedicated to discovering and commercializing innovative medicines for rare disorders, leveraging its scientific expertise and robust global commercial infrastructure.

PTC Therapeutics (NASDAQ: PTCT) will host a webinar on April 15 at 9 a.m. E.T. discussing its PTC518 Huntington disease (HD) program. The webinar will cover PTC's splicing platform and showcase the ongoing Phase 1 clinical trial of PTC518. Preliminary results indicate that PTC518 effectively reduces Huntingtin protein levels in both brain and blood. Participants can join via phone or a live webcast on the PTC website, with a replay available post-event. Huntington disease affects about 45,000 people in the U.S., primarily those aged 30-50.